Short Interest in Capricor Therapeutics Inc (NASDAQ:CAPR) Expands By 26.8%

Capricor Therapeutics Inc (NASDAQ:CAPR) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 5,590,000 shares, an increase of 26.8% from the November 30th total of 4,410,000 shares. Based on an average daily trading volume, of 3,570,000 shares, the short-interest ratio is presently 1.6 days.

Analyst Upgrades and Downgrades

Several research analysts have commented on CAPR shares. HC Wainwright reiterated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Thursday, November 14th. Maxim Group lifted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 target price on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Finally, Cantor Fitzgerald upped their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.50.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. State Street Corp lifted its holdings in shares of Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after buying an additional 111,291 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Capricor Therapeutics during the third quarter valued at approximately $3,806,000. PFM Health Sciences LP bought a new position in Capricor Therapeutics during the third quarter valued at approximately $2,324,000. Renaissance Technologies LLC lifted its stake in Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after acquiring an additional 84,350 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in Capricor Therapeutics in the second quarter worth approximately $426,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Stock Down 2.3 %

Capricor Therapeutics stock opened at $13.76 on Tuesday. Capricor Therapeutics has a 12 month low of $3.52 and a 12 month high of $23.40. The stock has a market cap of $625.67 million, a P/E ratio of -12.98 and a beta of 3.98. The company’s fifty day simple moving average is $17.23 and its 200-day simple moving average is $10.70.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.